craft-sa-dev Home  

PMC:1283364 / 0-525 JSONTXT 4 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T136 0-10 JJ denotes Persistent
T138 0-104 sentence denotes Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease
T137 11-22 NN denotes Amyloidosis
T139 23-32 VBG denotes following
T140 33-44 NN denotes Suppression
T141 45-47 IN denotes of
T142 48-50 NN denotes Aβ
T143 51-61 NN denotes Production
T144 62-64 IN denotes in
T145 65-66 DT denotes a
T147 67-77 JJ denotes Transgenic
T146 78-83 NN denotes Model
T148 84-86 IN denotes of
T149 87-96 NNP denotes Alzheimer
T150 97-104 NN denotes Disease
T151 104-105 sentence denotes
T152 154-164 sentence denotes Background
T153 154-164 NN denotes Background
T154 164-373 sentence denotes The proteases (secretases) that cleave amyloid-β (Aβ) peptide from the amyloid precursor protein (APP) have been the focus of considerable investigation in the development of treatments for Alzheimer disease.
T155 165-168 DT denotes The
T157 169-178 NNS denotes proteases
T158 179-180 -LRB- denotes (
T156 180-190 NNS denotes secretases
T160 190-191 -RRB- denotes )
T161 192-196 WDT denotes that
T162 197-203 VBP denotes cleave
T163 204-211 NN denotes amyloid
T165 211-212 HYPH denotes -
T164 212-213 NN denotes β
T167 214-215 -LRB- denotes (
T168 215-217 NN denotes Aβ
T169 217-218 -RRB- denotes )
T166 219-226 NN denotes peptide
T170 227-231 IN denotes from
T171 232-235 DT denotes the
T173 236-243 NN denotes amyloid
T174 244-253 NN denotes precursor
T172 254-261 NN denotes protein
T175 262-263 -LRB- denotes (
T176 263-266 NN denotes APP
T177 266-267 -RRB- denotes )
T178 268-272 VBP denotes have
T159 273-277 VBN denotes been
T179 278-281 DT denotes the
T180 282-287 NN denotes focus
T181 288-290 IN denotes of
T182 291-303 JJ denotes considerable
T183 304-317 NN denotes investigation
T184 318-320 IN denotes in
T185 321-324 DT denotes the
T186 325-336 NN denotes development
T187 337-339 IN denotes of
T188 340-350 NNS denotes treatments
T189 351-354 IN denotes for
T190 355-364 NNP denotes Alzheimer
T191 365-372 NN denotes disease
T192 372-373 . denotes .
T194 374-377 DT denotes The
T195 378-388 NN denotes prediction
T197 389-392 VBZ denotes has
T196 393-397 VBN denotes been
T198 398-402 IN denotes that
T200 403-411 VBG denotes reducing
T201 412-414 NN denotes Aβ
T202 415-425 NN denotes production
T203 426-428 IN denotes in
T204 429-432 DT denotes the
T205 433-438 NN denotes brain
T206 438-440 , denotes ,
T207 440-444 RB denotes even
T208 445-450 IN denotes after
T209 451-454 DT denotes the
T210 455-460 NN denotes onset
T211 461-463 IN denotes of
T212 464-472 JJ denotes clinical
T213 473-481 NNS denotes symptoms
T214 482-485 CC denotes and
T215 486-489 DT denotes the
T216 490-501 NN denotes development
T217 502-504 IN denotes of
T218 505-515 VBN denotes associated
T219 516-525 NN denotes pathology
R10 T147 T146 amod Transgenic,Model
R11 T148 T146 prep of,Model
R12 T149 T150 compound Alzheimer,Disease
R13 T150 T148 pobj Disease,of
R14 T155 T156 det The,secretases
R15 T156 T159 nsubj secretases,been
R16 T157 T156 nmod proteases,secretases
R17 T158 T156 punct (,secretases
R18 T160 T156 punct ),secretases
R19 T161 T162 dep that,cleave
R2 T139 T137 prep following,Amyloidosis
R20 T162 T156 relcl cleave,secretases
R21 T163 T164 nmod amyloid,β
R22 T164 T166 nmod β,peptide
R23 T165 T164 punct -,β
R24 T166 T162 dobj peptide,cleave
R25 T167 T164 punct (,β
R26 T168 T164 appos Aβ,β
R27 T169 T166 punct ),peptide
R28 T170 T162 prep from,cleave
R29 T171 T172 det the,protein
R3 T140 T139 pobj Suppression,following
R30 T172 T170 pobj protein,from
R31 T173 T172 compound amyloid,protein
R319 T136 T137 amod Persistent,Amyloidosis
R32 T174 T172 compound precursor,protein
R33 T175 T172 punct (,protein
R34 T176 T172 appos APP,protein
R35 T177 T159 punct ),been
R36 T178 T159 aux have,been
R37 T179 T180 det the,focus
R38 T180 T159 attr focus,been
R39 T181 T180 prep of,focus
R4 T141 T140 prep of,Suppression
R40 T182 T183 amod considerable,investigation
R41 T183 T181 pobj investigation,of
R42 T184 T183 prep in,investigation
R43 T185 T186 det the,development
R44 T186 T184 pobj development,in
R45 T187 T186 prep of,development
R46 T188 T187 pobj treatments,of
R47 T189 T188 prep for,treatments
R48 T190 T191 compound Alzheimer,disease
R49 T191 T189 pobj disease,for
R5 T142 T143 compound Aβ,Production
R50 T192 T159 punct .,been
R51 T194 T195 det The,prediction
R52 T195 T196 nsubj prediction,been
R53 T197 T196 aux has,been
R57 T201 T202 compound Aβ,production
R58 T202 T200 dobj production,reducing
R59 T203 T200 prep in,reducing
R6 T143 T141 pobj Production,of
R60 T204 T205 det the,brain
R61 T205 T203 pobj brain,in
R63 T207 T208 advmod even,after
R65 T209 T210 det the,onset
R66 T210 T208 pobj onset,after
R67 T211 T210 prep of,onset
R68 T212 T213 amod clinical,symptoms
R69 T213 T211 pobj symptoms,of
R7 T144 T140 prep in,Suppression
R70 T214 T210 cc and,onset
R71 T215 T216 det the,development
R72 T216 T210 conj development,onset
R73 T217 T216 prep of,development
R74 T218 T219 amod associated,pathology
R75 T219 T217 pobj pathology,of
R8 T145 T146 det a,Model
R9 T146 T144 pobj Model,in